A phase 2 study of the efficacy and safety of muvalaplin (LY3473329) in adults with elevated Lp(a) at high risk of cardiovascular (CV) events
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
